Cargando…

Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial

BACKGROUND: Metabolic disturbances, obesity and life-shortening cardiovascular morbidity are major clinical problems among patients with antipsychotic treatment. Especially two of the most efficacious antipsychotics, clozapine and olanzapine, cause weight gain and metabolic disturbances. Additionall...

Descripción completa

Detalles Bibliográficos
Autores principales:	Larsen, Julie Rask, Vedtofte, Louise, Holst, Jens Juul, Oturai, Peter, Kjær, Andreas, Corell, Christoph U, Vilsbøll, Tina, Fink-Jensen, Anders
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2014
Materias:	Diabetes and Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3975765/ https://www.ncbi.nlm.nih.gov/pubmed/24667381 http://dx.doi.org/10.1136/bmjopen-2013-004227

Ejemplares similares

The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial
por: Foghsgaard, Signe, et al.
Publicado: (2013)

The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial
por: Larsen, Emil List, et al.
Publicado: (2017)

Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet
por: Jensen, Simon Birk Kjær, et al.
Publicado: (2019)

Separate and combined effects of long-term GIP and GLP-1 receptor activation in patients with type 2 diabetes: a structured summary of a study protocol for a double-blind, randomised, placebo-controlled clinical trial
por: Helsted, Mads M, et al.
Publicado: (2023)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond – New Insights 2015
por: Gallwitz, Baptist
Publicado: (2015)

Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo-controlled trial
por: Sidelmann Christensen, Alexander, et al.
Publicado: (2018)

What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?
por: Holst, Jens Juul
Publicado: (2021)

Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes—a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study
por: Dejgaard, Thomas Fremming, et al.
Publicado: (2015)

Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial
por: Johansen, Nicklas Järvelä, et al.
Publicado: (2018)

Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence: study protocol of a randomised, double-blinded, placebo-controlled clinical trial
por: Antonsen, Kerstin K, et al.
Publicado: (2018)

Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes
por: Kaneko, Shizuka
Publicado: (2022)

Effect of GLP‐1 receptor agonist treatment on body weight in obese antipsychotic‐treated patients with schizophrenia: a randomized, placebo‐controlled trial
por: Ishøy, Pelle L., et al.
Publicado: (2016)

Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes
por: Holst, Jens J., et al.
Publicado: (2011)

Glucose-Dependent Insulinotropic Polypeptide: A Bifunctional Glucose-Dependent Regulator of Glucagon and Insulin Secretion in Humans
por: Christensen, Mikkel, et al.
Publicado: (2011)

Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry)
por: Sass, Marie Reeberg, et al.
Publicado: (2023)

FRI657 Case Series On GLP-1 Receptor Agonist Related Acute Pancreatitis
por: Kumar Kulkarni, Abhigna Uday, et al.
Publicado: (2023)

THU334 Trends In GLP-1 Agonist Utilization In Diabetics With And Without Vascular Disease
por: Sargin, Pinar, et al.
Publicado: (2023)

Study protocol of the randomised placebo-controlled GLOBE trial: GLP-1 for bridging of hyperglycaemia during cardiac surgery
por: Hulst, Abraham H, et al.
Publicado: (2018)

RF04 | PSUN295 Evolution of Monomeric Multi-Agonists of GLP-1 and NPY Receptors
por: Chichura, Kylie, et al.
Publicado: (2022)

GLP-1 receptor agonists as promising disease-modifying agents in WFS1 spectrum disorder
por: Panfili, Eleonora, et al.
Publicado: (2023)

FRI652 Type 2 Diabetes Management: More GLP1 Agonists And Less Metformin?
por: Lopez Maldonado, Francisco J, et al.
Publicado: (2023)

Management of Late Dumping Syndrome Induced Hypoglycemia With GLP-1R Agonist
por: Shaghouli, Amna Ali, et al.
Publicado: (2021)

Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist—protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol
por: Ishøy, Pelle L, et al.
Publicado: (2014)

ODP259 Evaluating the Efficacy and Safety of Long-Acting GLP-1 Receptor Agonist in T1DM Patients
por: Mohandas, Deene, et al.
Publicado: (2022)

From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
por: Holst, Jens Juul
Publicado: (2019)

Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain
por: Conget, Ignacio, et al.
Publicado: (2016)

Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a systematic review
por: González-González, José Gerardo, et al.
Publicado: (2021)

RF28 | PSUN182 Risk of Pancreatitis After Glp-1 Receptor Agonist in Individuals With Known History of Pancreatitis
por: Kodali, Alimitha M, et al.
Publicado: (2022)

Switching between GLP‐1 receptor agonists in clinical practice: Expert consensus and practical guidance
por: Jain, Akshay B., et al.
Publicado: (2020)

Effects of liraglutide on gallbladder emptying: A randomized, placebo‐controlled trial in adults with overweight or obesity
por: Nexøe‐Larsen, Christina C., et al.
Publicado: (2018)

GLP-1 and Intestinal Diseases
por: Hunt, Jenna Elizabeth, et al.
Publicado: (2021)

Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes
por: Gluud, Lise L, et al.
Publicado: (2014)

MON-LB028 Comparing Cardiovascular Effects of GLP-1 Agonists in a Real World Setting
por: Wallia, Amisha, et al.
Publicado: (2019)

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
por: Hartman, Mark L., et al.
Publicado: (2020)

Clinical Management of Nonalcoholic Steatohepatitis (NASH) With the Use of Thiazolidinediones and the Additive Effect of Thiazolidinediones and a GLP-1 Agonist: Case Series
por: Rojas Ortiz, Valentina, et al.
Publicado: (2021)

PSUN172 Prescribing SGLT-2 Inhibitors and GLP-1 Agonists in Primary Care: Improving Rates of Guideline-Concordant Practice
por: Schuetz, Samantha, et al.
Publicado: (2022)

One Year’s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial
por: Vedtofte, Louise, et al.
Publicado: (2020)

A randomized double-blind study of testosterone replacement therapy or placebo in testicular cancer survivors with mild Leydig cell insufficiency (Einstein-intervention)
por: Bandak, Mikkel, et al.
Publicado: (2017)

Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis
por: Ma, Hong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2f6vdo659i6em79svschkbidt6